Do weight loss injections make you look old? What the evidence actually shows

What the trial data tells us about body composition and the face

The large-scale SURMOUNT-1 trial, published in the New England Journal of Medicine, recorded average weight reductions of around 20–21% at the highest tirzepatide dose over 72 weeks. STEP 1, the equivalent trial for semaglutide 2.4mg, showed roughly 15% average reduction. Neither trial was designed to measure facial aesthetics, which means there is no controlled evidence that GLP-1 medicines cause a specific 'aged' facial appearance, what the data does show is substantial, sustained fat loss, and fat is distributed throughout the body, including the face.

The face contains buccal fat pads and subcutaneous fat that contribute to what clinicians call mid-face volume. When total body fat falls sharply, that volume can reduce, and the overlying skin (if it has lost some elasticity with age) may not fully rebound. This is sometimes called 'Ozempic face' in the press, though the term is informal and misleading: the same effect occurs after bariatric surgery, crash diets or any rapid weight loss. The medicine is not the cause; the speed and scale of fat loss is.

It is also worth noting that carrying excess weight for many years can itself accelerate certain markers of biological ageing. The same trials that showed significant weight loss also showed improvements in blood pressure, blood sugar, cholesterol and inflammatory markers, factors with their own relationship to how the body ages over time.

Why muscle loss amplifies the effect, and how to limit it

One of the questions our prescribers hear regularly is whether weight loss injections affect muscle as well as fat. The honest answer is yes, to a degree, all significant calorie deficits carry some risk of lean-tissue loss alongside fat loss. Muscle provides structural support beneath the skin, so losing it contributes to the hollowed or slack appearance some people notice.

Protein intake is probably the single most modifiable factor here. Aiming for adequate dietary protein throughout treatment (your prescriber or a registered dietitian can advise on what adequate means for your weight and activity level) helps signal to the body that lean tissue should be preserved. Resistance exercise matters too: strength training during weight loss is consistently associated with better muscle retention in clinical research. These are not optional extras; they are part of how GLP-1 treatment works best.

Titration speed is another lever. Both Mounjaro and Wegovy use a gradual dose-escalation schedule precisely because slower escalation tends to produce fewer side effects and, by extension, a more sustainable rate of weight loss. Your prescriber sets and reviews your dose; if you are losing weight very rapidly or finding the pace difficult, that is a conversation to have with them directly. Bone and muscle changes are among the reasons clinical monitoring matters throughout treatment, not just at the start.

Skin laxity: what we know and what remains uncertain

Skin laxity after weight loss is governed by collagen content, elastin, hydration, genetics and age, none of which GLP-1 medicines appear to alter directly. The NHS patient information on tirzepatide lists the known side effects in detail; skin ageing or laxity does not appear among them. What does appear is a range of gastrointestinal effects that can, if severe, affect hydration, and feeling unwell during dose increases can make people less likely to eat adequate protein or exercise regularly, which brings us back to the compounding factors above.

Dehydration dull skin looks older. If nausea or reduced appetite is making it hard to drink enough or eat enough varied food, that is something to raise with your clinical team sooner rather than later. There are practical adjustments that can help, and if you are wondering whether weight loss injections make you sick more broadly, that question is covered in detail elsewhere on this site. No one should be sitting with manageable side effects in silence.

Some people find the visible facial change more noticeable than others, and that is partly about starting point, partly about speed of loss and partly about genetics. If you are already anxious about this before starting treatment, it is worth discussing realistic expectations with your prescriber. That is what the consultation is for.

Putting it in perspective: ageing versus health

It is understandable to feel conflicted. You may be seeking treatment because of real health risks (elevated blood pressure, joint strain, pre-diabetes) while also caring about how you look. Both are legitimate, and neither cancels the other out.

The evidence base for GLP-1 medicines in people with clinically significant weight concerns is now substantial. NICE's appraisal of tirzepatide, TA1026, concluded that the health gains across blood pressure, blood sugar and cardiovascular risk markers justify its recommendation for eligible adults. Those gains are not cosmetic. A face that looks slightly leaner is a cosmetic concern; a meaningful reduction in cardiovascular risk is a clinical one.

Practical steps that most prescribers recommend alongside treatment with a weight loss injection include staying well-hydrated, aiming for 1.2–1.6g of protein per kilogram of body weight daily, doing some form of resistance exercise at least twice a week, and not rushing the pace of loss. None of those require a separate product or a specialist clinic. They are habits. And they make a measurable difference to body composition outcomes.

If you are also curious about other physical changes people ask about (fatigue during treatment or temporary hair shedding) those are covered separately. Both are worth reading before you start.

If you would like to understand how treatment is assessed for your specific situation, the free consultation at nume is the place to begin. A GPhC-registered prescriber reviews your information the same day, no algorithm, no automated approval.